US Edition
HI-PEITHO Trial Demonstrates Boston Scientific EKOS™ Endovascular System Is Superior to Standard of Care for Treatment of Acute Pulmonary Embolism
The EKOS system cut clinical events by 61% in a 544-patient trial of intermediate-risk pulmonary embolism with no increase in major bleeding or brain hemorrhage.
- On Saturday, Boston Scientific announced positive results from the HI-PEITHO trial at the American College of Cardiology meeting, showing the EKOS Endovascular System reduced composite clinical events by 61% in intermediate-risk pulmonary embolism patients versus anticoagulation alone.
- Intermediate-Risk pulmonary embolism patients have historically occupied a treatment gray area; the 2014 PEITHO trial using systemic thrombolysis showed mixed results with significant bleeding risks, leaving clinicians uncertain how to intervene.
- The 544-patient study showed a composite event rate of 4.0% with the EKOS device compared to 10.3% for standard anticoagulation at 7 days, with major bleeding rates at 7 days comparable between groups .
- Joshua Beckman, chief of vascular medicine at University of Texas Southwestern Medical School in Dallas, called the strategy a "breakthrough," though Lauren Westafer of UMass Chan Medical School-Baystate cautioned that "health systems must weigh increased resource utilization" against marginal benefits.
- Clinicians await 6- and 12-month follow-up data to confirm durability of results, as the field shifts toward preserving long-term quality of life; nearly 50% of pulmonary embolism patients remain significantly impaired 1 year after diagnosis.
26 Articles
26 Articles
HI-PEITHO Kicks Off 'Golden Era' in Pulmonary Embolism
(MedPage Today) -- NEW ORLEANS -- A major advance for the treatment of intermediate-risk pulmonary embolism (PE) arrived with HI-PEITHO's landmark report on ultrasound-facilitated, catheter-directed thrombolysis (CDT). In this hard-to-treat...
Boston Scientific Corporation (BSX) Presents at American College of Cardiology 75th Annual Scientific Session and Expo Transcript
Operator Good evening, and welcome to the Boston Scientific American College of Cardiology Conference Call. [Operator Instructions] Please note, this event is being recorded. I would now like to turn the conference over to Lauren Tengler, Vice President, Investor Relations. Please go ahead. Lauren TenglerDirector of Investor Relations Thanks, Drew. Thanks to everyone for joining us. With me to discuss our CHAMPION-AF and HI-PEITHO trials are Dr…
Boston Scientific Unveils “Practice-Transforming” Trial Data for PE and AF at ACC Conference Call
Boston Scientific (NYSE:BSX) executives highlighted new data from two randomized clinical trials during an American College of Cardiology conference call, describing the results as potentially “practice transforming” for pulmonary embolism (PE) and stroke prevention in atrial fibrillation (AF). The company discussed HI-PEITHO, which evaluated ultrasound-assisted catheter-directed thrombolysis with the EkoSonic system in intermediate-risk PE, and…
Interventional News
Cardiovascular NewsHI-PEITHO finds catheter-based procedure improves pulmonary embolism outcomes
Stavros V Konstantinides, lead author of the HI-PEITHO study Patients who underwent ultrasound-facilitated, catheter-directed fibrinolysis for acute pulmonary embolism (PE) had significantly better outcomes than those who received standard systemic anticoagulants, according to a study presented today at the American College of Cardiology’s Annual Scientific Session (ACC.26; 28–30 March, New Orleans, USA). The targeted catheter-based approach red…
Coverage Details
Bias Distribution
- 88% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
